id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
ecj-14072	Bologna, Carolina; Ferraro, Andrea; Augiero, Antonio; Nuzzo, Vincenzo; Guiotto, Giovanna	How to manage a severe form of euglycemic diabetic ketoacidosis caused by SGLT2 inhibitors: a case report and literature review	2025	5	.pdf	application/pdf	4393	222	50	How to manage a severe form of euglycemic diabetic ketoacidosis caused by SGLT2 inhibitors: a case report and literature review Carolina Bologna,1 Andrea Ferraro,2 Antonio Augiero,2 Vincenzo Nuzzo,1 Giovanna Guiotto2 1Internal Medicine Unit, Ospedale del Mare, ASL Na1 Centro, Naples; 2Emergency Unit, Ospedale del Mare, ASL Na1 Centro, Naples, Italy Highlights - Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors can cause a rare but fatal side effect known as Euglycemic Diabetic Ketoacidosis (EDKA); - EDKA is an endocrine emergency characterized by elevated ketone bodies and metabolic acidosis despite normal or near- normal blood glucose levels that typically manifests with nausea, vomiting, malaise, or fatigue; - Management is based on immediate discontinuation of the glifozine, hydration, insulin therapy and bicarbonates; - The therapy is often difficult due to the presence of hypokalemia and a vicious circle between glucagon and insulin; - Octreotide can be used to reduce insulin secretion and stabilize blood glucose levels without further insulin administration. The increase in glucagon is likely an indirect effect mediated by the reduction in insulin secre- tion, as there is no evidence to suggest a direct stimulation of the pancreatic alpha cells by SGLT2 inhibitors.	cache/ecj-14072.pdf	txt/ecj-14072.txt